The 2026 Semaglutide Patent Expiry: Transformation of the Indian Metabolic Healthcare Landscape

Ratnesh Jain (ICT Mumbai; Mumbai Biocluster)

Mumbai Biocluster White Paper MBC_WHITEPAPER_002 · 20 Mar 2026 · PDF · 6.3 MB

Summary

Analyses the expiry of core semaglutide patent protection in India on March 20, 2026 and the wave of generic launches that followed, including approvals, pricing and accessibility strategies.